Study for Improving Maternal Pregnancy And Child ouTcomes (IMPACT): a study protocol for a Swedish prospective multicentre cohort study

Lina Bergman, Anna Sandström, Bo Jacobsson, Stefan Hansson, Peter Lindgren, Anders Larsson, Henrik Imberg, Peter Conner, Marius Kublickas, Ylva Carlsson, Anna-Karin Wikström, Lina Bergman, Anna Sandström, Bo Jacobsson, Stefan Hansson, Peter Lindgren, Anders Larsson, Henrik Imberg, Peter Conner, Marius Kublickas, Ylva Carlsson, Anna-Karin Wikström

Abstract

Introduction: First-trimester pregnancy risk evaluation facilitates individualised antenatal care, as well as application of preventive strategies for pre-eclampsia or birth of a small for gestational age infant. A range of early intervention strategies in pregnancies identified as high risk at the end of the first trimester has been shown to decrease the risk of preterm pre-eclampsia (<37 gestational weeks). The aim of this project is to create the Improving Maternal Pregnancy And Child ouTcomes (IMPACT) database; a nationwide database with individual patient data, including predictors recorded at the end of the first trimester and later pregnancy outcomes, to identify women at high risk of pre-eclampsia. A second aim is to link the IMPACT database to a biobank with first-trimester blood samples.

Methods and analysis: This is a Swedish prospective multicentre cohort study. Women are included between the 11th and 14th weeks of pregnancy. At inclusion, pre-identified predictors are retrieved by interviews and medical examinations. Blood samples are collected and stored in a biobank. Additional predictors and pregnancy outcomes are retrieved from the Swedish Pregnancy Register. Inclusion in the study began in November 2018 with a targeted sample size of 45 000 pregnancies by end of 2021. Creation of a new risk prediction model will then be developed, validated and implemented. The database and biobank will enable future research on prediction of various pregnancy-related complications.

Ethics and dissemination: Confidentiality aspects such as data encryption and storage comply with the General Data Protection Regulation and with ethical committee requirements. This study has been granted national ethical approval by the Swedish Ethical Review Authority (Uppsala 2018-231) and national biobank approval at Uppsala Biobank (18237 2 2018 231). Results from the current as well as future studies using information from the IMPACT database will be published in peer-reviewed journals.

Trial registration number: NCT03831490.

Keywords: first-trimester screening; mean arterial pressure; placental growth factor; preeclampsia.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study design for the IMPACT database and the IMPACT biobank. IMPACT, Improving Maternal Pregnancy And Child ouTcomes; PlGF, placental growth factor.
Figure 2
Figure 2
Study design for creation and validation of a prediction model for pre-eclampsia and birth of a small for gestational age infant. IMPACT; Improving Maternal Pregnancy And Child ouTcomes.

References

    1. Rolnik DL, Wright D, Poon LC, et al. . Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017;377:613–22. 10.1056/NEJMoa1704559
    1. Middleton P, Gomersall JC, Gould JF, et al. . Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev 2018;11:CD003402. 10.1002/14651858.CD003402.pub3
    1. Norman JE, Marlow N, Messow C-M, et al. . Does progesterone prophylaxis to prevent preterm labour improve outcome? a randomised double-blind placebo-controlled trial (OPPTIMUM). Health Technol Assess 2018;22:1–304. 10.3310/hta22350
    1. Andrikopoulou M, Purisch SE, Handal-Orefice R, et al. . Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol 2018;219:399 e1–6. 10.1016/j.ajog.2018.06.011
    1. Cedergren MI. Optimal gestational weight gain for body mass index categories. Obstet Gynecol 2007;110:759–64. 10.1097/01.AOG.0000279450.85198.b2
    1. Hutcheon JA, Stephansson O, Cnattingius S, et al. . Pregnancy weight gain before diagnosis and risk of preeclampsia: a population-based cohort study in nulliparous women. Hypertension 2018;72:433–41. 10.1161/HYPERTENSIONAHA.118.10999
    1. Mol BWJ, Roberts CT, Thangaratinam S, et al. . Pre-Eclampsia. Lancet 2016;387:999–1011. 10.1016/S0140-6736(15)00070-7
    1. WHO, 2011. Available:
    1. Lindqvist PG, Molin J. Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? Ultrasound Obstet Gynecol 2005;25:258–64. 10.1002/uog.1806
    1. Akolekar R, Syngelaki A, Poon L, et al. . Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8–15. 10.1159/000341264
    1. Bujold E, Roberge S, Lacasse Y, et al. . Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–14. 10.1097/AOG.0b013e3181e9322a
    1. Wright D, Syngelaki A, Akolekar R, et al. . Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015;213:62 e1–10. 10.1016/j.ajog.2015.02.018
    1. Mosimann B, Pfiffner C, Amylidi-Mohr S, et al. . First trimester combined screening for preeclampsia and small for gestational age - a single centre experience and validation of the FMF screening algorithm. Swiss Med Wkly 2017;147:w14498. 10.4414/smw.2017.14498
    1. Lobo GAR, Nowak PM, Panigassi AP, et al. . Validation of fetal medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population. J Matern Fetal Neonatal Med 2019;32:286–92. 10.1080/14767058.2017.1378332
    1. Cheng Y, Leung TY, Law LW, et al. . First trimester screening for pre-eclampsia in Chinese pregnancies: case-control study. BJOG 2018;125:442–9. 10.1111/1471-0528.14970
    1. Chaemsaithong P, Pooh RK, Zheng M, et al. . Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol 2019;221:650.e1–650.e16. 10.1016/j.ajog.2019.09.041
    1. O'Gorman N, Wright D, Syngelaki A, et al. . Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016;214:103 e1–e12. 10.1016/j.ajog.2015.08.034
    1. Bartsch E, Medcalf KE, Park AL, et al. . Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016;353:i1753. 10.1136/bmj.i1753
    1. Suhag A, Berghella V. Intrauterine growth restriction (IUGR): etiology and diagnosis. Curr Obstet Gynecol Rep 2013;2:102–11. 10.1007/s13669-013-0041-z
    1. Al-Rubaie Z, Askie LM, Ray JG, et al. . The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review. BJOG 2016;123:1441–52. 10.1111/1471-0528.14029
    1. Stephansson O, Petersson K, Björk C, et al. . The Swedish Pregnancy Register - for quality of care improvement and research. Acta Obstet Gynecol Scand 2018;97:466–76. 10.1111/aogs.13266
    1. Townsend R, Khalil A, Premakumar Y, et al. . Prediction of pre-eclampsia: review of reviews. Ultrasound Obstet Gynecol 2019;54:16–27. 10.1002/uog.20117
    1. Karagiannis G, Akolekar R, Sarquis R, et al. . Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2011;29:148–54. 10.1159/000321694
    1. Poon LCY, Zymeri NA, Zamprakou A, et al. . Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther 2012;31:42–8. 10.1159/000335366
    1. Khalil A, Nicolaides KH. How to record uterine artery Doppler in the first trimester. Ultrasound Obstet Gynecol 2013;42:478–9. 10.1002/uog.12366
    1. Plasencia W, Maiz N, Bonino S, et al. . Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007;30:742–9. 10.1002/uog.5157
    1. MedSciNet. Available:
    1. Wright D, Akolekar R, Syngelaki A, et al. . A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 2012;32:171–8. 10.1159/000338470
    1. De Paco C, Kametas N, Rencoret G, et al. . Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of preeclampsia and small for gestational age. Obstet Gynecol 2008;111:292–300. 10.1097/01.AOG.0000298622.22494.0c
    1. Marsál K, Persson PH, Larsen T, et al. . Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996;85:843–8. 10.1111/j.1651-2227.1996.tb14164.x
    1. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285–93. 10.1126/science.3287615
    1. Harrell FE, Lee KL, Califf RM, et al. . Regression modelling strategies for improved prognostic prediction. Stat Med 1984;3:143–52. 10.1002/sim.4780030207
    1. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J 2014;35:1925–31. 10.1093/eurheartj/ehu207
    1. Pavlou M, Ambler G, Seaman SR, et al. . How to develop a more accurate risk prediction model when there are few events. BMJ 2015;351:h3868. 10.1136/bmj.h3868
    1. Vergouwe Y, Steyerberg EW, Eijkemans MJC, et al. . Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol 2005;58:475–83. 10.1016/j.jclinepi.2004.06.017
    1. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med 2016;35:214–26. 10.1002/sim.6787
    1. Hofmann R, James SK, Jernberg T, et al. . Oxygen therapy in suspected acute myocardial infarction. N Engl J Med 2017;377:1240–9. 10.1056/NEJMoa1706222
    1. Vangen S, Bødker B, Ellingsen L, et al. . Maternal deaths in the Nordic countries. Acta Obstet Gynecol Scand 2017;96:1112–9. 10.1111/aogs.13172

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel